<< Back
Steve Gilman, Ph.D.
Board Member

Dr. Gilman joined the Board in April 2016 and brings more than 28 years of scientific and development expertise in the healthcare industry. Dr. Gilman served most recently as chief scientific officer of Cubist Pharmaceuticals until its acquisition by Merck & Co. Prior to joining Cubist, he served as chairman of the Board of Directors and chief executive officer of ActivBiotics, a privately held biopharmaceutical company. Previously, Dr. Gilman worked at Millennium Pharmaceuticals, Inc., where he held a number of senior leadership roles including vice president and general manager of Inflammation. Prior to Millennium, he was group director at Pfizer Global Research and Development, where he was responsible for drug discovery of several therapeutic areas, including immunology and antibacterials. Dr. Gilman has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School, and Connecticut College. He currently serves as chairman and interim CEO of ContraFect Corporation (Nasdaq:CFRX) and on the board of directors of Vericel (Nasdaq:VCEL), SCYNEXIS (Nasdaq:SCYX), the Massachusetts Biotechnology Association, the Northeastern University Drug Discovery Advisory Board and the Penn State University Biotechnology Advisory Board. Dr. Gilman received his M.S. and Ph.D. degrees in microbiology from Pennsylvania State University, his post-doctoral training at Scripps Clinic and Research Foundation, and received a B.A. in microbiology from Miami University of Ohio.